Annual CFI
-$179.09 M
-$233.84 M-427.08%
31 December 2023
Summary:
Viking Therapeutics annual cash flow from investing activities is currently -$179.09 million, with the most recent change of -$233.84 million (-427.08%) on 31 December 2023. During the last 3 years, it has fallen by -$220.65 million (-530.84%). VKTX annual CFI is now -427.08% below its all-time high of $54.75 million, reached on 31 December 2022.VKTX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$25.90 M
+$151.96 M+120.55%
30 September 2024
Summary:
Viking Therapeutics quarterly cash flow from investing activities is currently $25.90 million, with the most recent change of +$151.96 million (+120.55%) on 30 September 2024. Over the past year, it has increased by +$38.44 million (+306.65%). VKTX quarterly CFI is now -27.52% below its all-time high of $35.73 million, reached on 31 December 2023.VKTX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$524.22 M
+$38.44 M+6.83%
30 September 2024
Summary:
Viking Therapeutics TTM cash flow from investing activities is currently -$524.22 million, with the most recent change of +$38.44 million (+6.83%) on 30 September 2024. Over the past year, it has dropped by -$316.66 million (-152.56%). VKTX TTM CFI is now -799.86% below its all-time high of $74.90 million, reached on 30 September 2022.VKTX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VKTX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -427.1% | +306.6% | -152.6% |
| 3 y3 years | -530.8% | +90.2% | -1384.3% |
| 5 y5 years | +32.6% | +70.9% | -323.2% |
VKTX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -427.1% | at low | -27.5% | +105.6% | -799.9% | +18.2% |
| 5 y | 5 years | -427.1% | +32.6% | -27.5% | +105.6% | -799.9% | +18.2% |
| alltime | all time | -427.1% | +32.6% | -27.5% | +105.6% | -799.9% | +18.2% |
Viking Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $25.90 M(-120.5%) | -$524.22 M(-6.8%) |
| June 2024 | - | -$126.06 M(-72.6%) | -$562.65 M(-12.2%) |
| Mar 2024 | - | -$459.79 M(-1386.7%) | -$641.08 M(+258.0%) |
| Dec 2023 | -$179.09 M(-427.1%) | $35.73 M(-385.1%) | -$179.09 M(-13.7%) |
| Sept 2023 | - | -$12.53 M(-93.9%) | -$207.56 M(+23.5%) |
| June 2023 | - | -$204.48 M(-9403.1%) | -$168.13 M(-403.9%) |
| Mar 2023 | - | $2.20 M(-69.7%) | $55.33 M(+1.1%) |
| Dec 2022 | $54.75 M(+44.2%) | $7.26 M(-73.0%) | $54.75 M(-26.9%) |
| Sept 2022 | - | $26.89 M(+41.7%) | $74.90 M(+21.5%) |
| June 2022 | - | $18.98 M(+1072.3%) | $61.63 M(+33.4%) |
| Mar 2022 | - | $1.62 M(-94.1%) | $46.21 M(+21.7%) |
| Dec 2021 | $37.96 M(-8.7%) | $27.41 M(+101.3%) | $37.96 M(-7.0%) |
| Sept 2021 | - | $13.62 M(+282.5%) | $40.82 M(+132.3%) |
| June 2021 | - | $3.56 M(-153.7%) | $17.57 M(-26.1%) |
| Mar 2021 | - | -$6.63 M(-121.9%) | $23.79 M(-42.8%) |
| Dec 2020 | $41.57 M(+457.0%) | $30.27 M(-414.2%) | $41.57 M(>+9900.0%) |
| Sept 2020 | - | -$9.63 M(-198.5%) | $237.00 K(-99.1%) |
| June 2020 | - | $9.78 M(-12.3%) | $25.02 M(-4.6%) |
| Mar 2020 | - | $11.15 M(-200.8%) | $26.22 M(+251.4%) |
| Dec 2019 | $7.46 M | -$11.06 M(-173.0%) | $7.46 M(-106.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | $15.15 M(+38.0%) | -$123.87 M(-25.4%) |
| June 2019 | - | $10.98 M(-244.3%) | -$166.11 M(-31.8%) |
| Mar 2019 | - | -$7.61 M(-94.7%) | -$243.71 M(-8.3%) |
| Dec 2018 | -$265.73 M(>+9900.0%) | -$142.39 M(+425.7%) | -$265.73 M(+108.0%) |
| Sept 2018 | - | -$27.09 M(-59.3%) | -$127.73 M(+28.7%) |
| June 2018 | - | -$66.63 M(+124.9%) | -$99.26 M(+197.2%) |
| Mar 2018 | - | -$29.63 M(+574.0%) | -$33.40 M(+1830.4%) |
| Dec 2017 | -$1.73 M(-157.1%) | -$4.40 M(-415.8%) | -$1.73 M(-142.1%) |
| Sept 2017 | - | $1.39 M(-282.0%) | $4.11 M(+30.1%) |
| June 2017 | - | -$765.00 K(-137.5%) | $3.16 M(-449.8%) |
| Mar 2017 | - | $2.04 M(+40.9%) | -$903.90 K(-129.8%) |
| Dec 2016 | $3.03 M(-122.5%) | $1.45 M(+228.2%) | $3.03 M(-14.4%) |
| Sept 2016 | - | $441.00 K(-109.1%) | $3.54 M(-2390.3%) |
| June 2016 | - | -$4.83 M(-180.9%) | -$154.50 K(-97.9%) |
| Mar 2016 | - | $5.97 M(+205.3%) | -$7.50 M(-44.3%) |
| Dec 2015 | -$13.47 M | $1.96 M(-160.1%) | -$13.47 M(-12.7%) |
| Sept 2015 | - | -$3.25 M(-73.3%) | -$15.43 M(+26.7%) |
| June 2015 | - | -$12.17 M(<-9900.0%) | -$12.17 M(<-9900.0%) |
| Mar 2015 | - | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2014 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2014 | - | $0.00 | $0.00 |
FAQ
- What is Viking Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Viking Therapeutics?
- What is Viking Therapeutics annual CFI year-on-year change?
- What is Viking Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Viking Therapeutics?
- What is Viking Therapeutics quarterly CFI year-on-year change?
- What is Viking Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Viking Therapeutics?
- What is Viking Therapeutics TTM CFI year-on-year change?
What is Viking Therapeutics annual cash flow from investing activities?
The current annual CFI of VKTX is -$179.09 M
What is the all time high annual CFI for Viking Therapeutics?
Viking Therapeutics all-time high annual cash flow from investing activities is $54.75 M
What is Viking Therapeutics annual CFI year-on-year change?
Over the past year, VKTX annual cash flow from investing activities has changed by -$233.84 M (-427.08%)
What is Viking Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of VKTX is $25.90 M
What is the all time high quarterly CFI for Viking Therapeutics?
Viking Therapeutics all-time high quarterly cash flow from investing activities is $35.73 M
What is Viking Therapeutics quarterly CFI year-on-year change?
Over the past year, VKTX quarterly cash flow from investing activities has changed by +$38.44 M (+306.65%)
What is Viking Therapeutics TTM cash flow from investing activities?
The current TTM CFI of VKTX is -$524.22 M
What is the all time high TTM CFI for Viking Therapeutics?
Viking Therapeutics all-time high TTM cash flow from investing activities is $74.90 M
What is Viking Therapeutics TTM CFI year-on-year change?
Over the past year, VKTX TTM cash flow from investing activities has changed by -$316.66 M (-152.56%)